ClinicalTrials.gg

Program

surzetoclax

Also written as “ABBV-453” and “Surzetoclax”.

In AbbVie's pipeline, BCL-2. Its studies are mostly in Multiple Myeloma · Leukemia, Lymphocytic, Chronic, B-Cell, led by AbbVie.

Furthest: phase 2, since Apr 17, 20253 company-led studies, 3 open or runningNext primary completion: Jul 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie33 open or runningphase 2since Apr 17, 2025Mar 25, 2022Jul 2027phase 1 · NCT06291220
  • Named in AbbVie’s own pipeline as Surzetoclax (ABBV-453), phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 25, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05308654 · 34 enrolled · United States, Australia, Israel and more
  2. Feb 27, 2024Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06291220 · 4 enrolled · United States, Australia, Germany and more
  3. Apr 17, 2025Phase 2 study in Multiple MyelomaNCT06953960 · 325 planned · United States, Australia, Belgium and more

Ahead

  1. Jul 2027Primary completion: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06291220
  2. Dec 2030Primary completion: phase 2 study in Multiple MyelomaNCT06953960

TargetBeta

“BCL-2”the company's pipeline, read by Claude · source

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
venetoclaxruleAbbViephase 483
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 38
lacutoclaxruleLupeng Pharmaceuticalphase 24
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 21
surzetoclaxAbbViephase 12
FXS0683Fosun Pharmaphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06953960Multiple Myeloma · United States, Australia, Belgium and more2RecruitingDec 2030325
NCT06291220Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Germany and more1Active, not recruitingJul 20274
NCT05308654Multiple Myeloma · United States, Australia, Israel and more1Active, not recruitingFeb 7, 202434

How it is read

Names in the registry

  • “ABBV-453”, 2 entries
  • “Surzetoclax”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.